Wider indications for treatment of chronic hepatitis B?

摘要

Recently, it was shown that the risk for hepatitis B virus (HBV) carriers to develop hepatocellular carcinoma (HCC) increases with increasing viral load , and it was proposed that one might consider long-term antiviral treatment for all carriers with HBV DNA levels above 10 000 copies/mL. This view may seem attractive as new oral antivirals with few side-effects and lower risk of resistance have become available. It may also seem rational as HCC might develop without necroinflammation as a result of transactivating effects of the X gene of HBV or integration of HBV DNA into the human genome.